BIONCARD, Identifying surrogate oncological outcome biomarkers: a translational study of anti-VEGF/TKI-induced cardiovascular effects in pan-cancer cohort patients
Funding Organization: 5x1000 Istituto Nazionale dei Tumori
Principal Investigator: Dott.ssa Vallerio Paola
Co Principal Investigator: Dott.ssa Veronese Chiara
Main Facility: Cardiologia
Therapies targeting vascular endothelial growth factor (VEGF) signalling, including tyrosine kinase inhibitors directed against VEGF receptors (VEGFR-TKIs), are important treatment options for several malignancies. However, they may also induce changes in blood pressure, arterial stiffness and cardiac function. Some of these changes may reflect the biological activity of treatment, but their significance in relation to cancer outcomes and cardiovascular toxicity remains incompletely understood.
BIONCARD is an observational, translational study seeking non-invasive cardiovascular biomarkers that could help monitor responses to anti-VEGF/VEGFR-TKI therapies across different cancer types. The project focuses on endothelial function, haemodynamic characteristics and early vascular and cardiac changes, assessing whether these measurements can provide additional information beyond the occurrence of hypertension alone.
By integrating clinical assessments, cardiovascular measurements and quantitative analyses, BIONCARD explores associations between vascular changes, treatment safety and oncological outcomes. It aims to identify potential early indicators and surrogate biomarkers for subsequent validation, with the longer-term goal of informing more personalised monitoring strategies and better-supported treatment decisions.
Principal Investigator Dr. Vallerio Paola
Co Principal Investigator Dr. Veronese Chiara
Cicchetti Alessandro
Struttura Principale: Cardiology
Complex Structure
Last update: 17/11/2026